PISCATAWAY, N.J., Sept. 12,
2024 /PRNewswire/ -- GenScript Biotech Corporation
("GenScript"), a global leader in life sciences products and
services, announced the appointment of Dr. Ross Allen Grossman as a Non-Executive Director
and Dr. Alphonse Galdes as an
Independent Non-Executive Director. These appointments not only
further diversify the Group's Board but also highlight GenScript's
commitment to building an international, diverse, and highly
specialized corporate governance team. With the addition of these
two directors, the company is better positioned to meet the
challenges of a complex global landscape and governance
requirements.
Dr. Grossman brings strategic insight and practical experience
from a global perspective, with over 35 years of leadership in
human resources across multinational financial services,
pharmaceutical and biotech companies. He has held key positions at
Prudential Financial, Novartis, and UBS AG (formerly Paine Webber),
and at Regeneron Pharmaceuticals, he led the building and
formulation of human resources infrastructure, process and strategy
to support the company's rapid expansion. Dr. Grossman joined
GenScript in 2023 and currently serves as a consultant for Legend
Biotech Corporation ("Legend Biotech"), a non-wholly owned
subsidiary of the Company.
Dr. Galdes' appointment strengthens GenScript's leading position
in drug discovery and biopharmaceutical chemistry and manufacturing
and controls ("CMC") development. With extensive experience at
industry leaders such as Biogen and a strong academic background in
chemistry and biology, Dr. Galdes' expertise will help drive
innovation and product development, advancing GenScript's mission
for high-quality growth in the biotech space.
In addition to these appointments, Legend Biotech has appointed
Dr. Peter Salovey, Ph.D., President
Emeritus of Yale University, as an
Independent Director on August 8,
2024. His deep experience and wealth of knowledge in medical
research and public health will bring a fresh and diversified
perspective to the company.
As a biotechnology company committed to global expansion,
GenScript continues to follow a strategy driven by innovation and
talent. These new appointments will enable the company to better
navigate global challenges and serve its international customer
base.
About GenScript Biotech Corporation
GenScript Biotech
Corporation (HK.1548) is a world leader in technologies and
services for life science R&D and manufacture. Built upon its
solid DNA synthesis technology, the company comprises four major
business units: a life-science services and products business unit,
a biologics contract development and manufacturing organization
(CDMO) business unit, an industrial synthetic products business
unit, and an integrated global cell therapy company. GenScript
accelerates scientific discovery and therapeutic breakthrough with
its customers. Since its founding in New
Jersey, USA in 2002, GenScript has expanded its operations
to serve more than 200,000 customers across 100 countries with a
dedicated team of 7,200 employees. As of June 30, 2024, over 100,000 peer-reviewed journal
articles worldwide had cited GenScript's services and products.
Guided by its mission to make people and nature healthier through
biotechnology, GenScript strives to become the most trustworthy
biotech company in the world.
For more information, please visit GenScript Biotech's official
website https://www.genscript.com
View original
content:https://www.prnewswire.com/news-releases/genscript-appoints-new-board-members-to-drive-global-growth-302246477.html
SOURCE GenScript Biotech Corporation